Health In Tech, Inc.
NASDAQ:HITSoftware - Application
+$0.00 today
- Market cap
- $50.13M
- Beta
- 2.94
- P/E (TTM)
- -75.2
- EPS (TTM)
- -$0.01
Volume 0.04M
Average 0.23M
HIT Inventory
Cash effect of the change in inventory; building inventory consumes cash.
Health In Tech, Inc.NASDAQ: HIT
Inventory · Q1 FY2026 · quarter ended Mar 2026
Inventory outflow grows to $0
Q1 FY2026 inventory was $0, compared with $0 a year earlier. Trailing-twelve-month inventory was $0.
Context
- Inventory amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Inventory increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly inventory holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Inventory history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Inventory | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Inventory vs competitors
How HIT compares with its peers on the latest reported figures
- Peers report in different currencies, so inventory is compared through growth and share of revenue rather than absolute size.
- Inventory amounts to 0.0% of revenue for HIT, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.14M USD | +19.4% | -30.2% | 2.1% | |
HITHealth In Tech, Inc. | LTM Mar 2026 | $0 USD | — | — | 0.0% |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| FY2025 | $0 USD | — | — | 0.0% | |
SVCOSilvaco Group, Inc. Common Stock | LTM Mar 2026 | $0 USD | — | — | 0.0% |
LAWRRobot Consulting Co., Ltd. ADS | FY2025 | ¥0 JPY | — | — | 0.0% |
TEADTeads Holding Co. | LTM Mar 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding HIT) | — | +19.4% | -30.2% | 0.0% | |
Competitors are the stored peer set for HIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (243.34K) | 3.96M | 670.48K | 1.28M |
| Depreciation & Amortization | 0 | 339.3K | 541.14K | 900.58K |
| Deferred Income Tax | 9K | 133.98K | (93.3K) | 429K |
| Stock-Based Compensation | 566.04K | 0 | 468.49K | 1.57M |
| Change in Working Capital | 451.06K | (2.89M) | 156.52K | (5.23M) |
| Accounts Receivables | (716K) | (2.94M) | 1.77M | (2.44M) |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 449.95K | 2.15M | (851.96K) | 2.36M |
| Other Working Capital | 717.1K | (2.09M) | (759.05K) | (5.15M) |
| Other Non-Cash Items | 0 | (16K) | 432.88K | 4.19M |
| Operating Cash Flow | 782.75K | 1.53M | 2.18M | 3.13M |
| Capital Expenditures | (1.22M) | (1.14M) | (900.76K) | (3.19M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (800K) | 64K | 64K |
| Investing Cash Flow | (1.22M) | (1.94M) | (836.76K) | (3.13M) |
| Debt Repayment | (74.09K) | 1.65M | (2.15M) | 0 |
| Common Stock Issued | 0 | 0 | 8.21M | 23.43K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (46.97K) | (306.12K) | (1.98M) | (210.82K) |
| Financing Cash Flow | 1.88M | 1.34M | 4.09M | (187.39K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.44M | 928.4K | 5.43M | (179.49K) |
| Free Cash Flow | (436.63K) | 384.52K | 1.28M | (56.11K) |
Health In Tech, Inc.
NASDAQ:HIT
Intrinsic Alpha fair value
Locked
Current Price
$0.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.